
Martin Metz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4344912/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1393-1414.	5.7	1,008
2	The <scp>EAACI</scp> / <scp>GA</scp> ² <scp>LEN</scp> / <scp>EDF</scp> / <scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 868-887.	5.7	912
3	The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 734-766.	5.7	392
4	Mast Cells Can Enhance Resistance to Snake and Honeybee Venoms. Science, 2006, 313, 526-530.	12.6	333
5	Control of murine hair follicle regression (catagen) by TGFâ€Î²1 <i>in vivo</i> . FASEB Journal, 2000, 14, 752-760.	0.5	301
6	Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature, 2004, 432, 512-516.	27.8	275
7	Mast cells in the promotion and limitation of chronic inflammation. Immunological Reviews, 2007, 217, 304-328.	6.0	275
8	Development and validation of the Urticaria Control Test: AÂpatient-reported outcome instrument for assessing urticaria control. Journal of Allergy and Clinical Immunology, 2014, 133, 1365-1372.e6.	2.9	268
9	The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA ² LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 780-802.	5.7	268
10	Mast cells – key effector cells in immune responses. Trends in Immunology, 2007, 28, 234-241.	6.8	264
11	Autoimmune chronic spontaneous urticaria: What we know and what we do not know. Journal of Allergy and Clinical Immunology, 2017, 139, 1772-1781.e1.	2.9	240
12	Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis. Journal of Dermatological Science, 2014, 73, 57-62.	1.9	222
13	lgE Mediated Autoallergy against Thyroid Peroxidase – A Novel Pathomechanism of Chronic Spontaneous Urticaria?. PLoS ONE, 2011, 6, e14794.	2.5	216
14	The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. Journal of Allergy and Clinical Immunology, 2015, 135, 337-342.e2.	2.9	208
15	Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. British Journal of Dermatology, 2006, 154, 294-298.	1.5	189
16	What is the physiological function of mast cells?. Experimental Dermatology, 2003, 12, 886-886.	2.9	187
17	Omalizumab treatment in patients with chronic inducible urticaria: AÂsystematic review of published evidence. Journal of Allergy and Clinical Immunology, 2018, 141, 638-649.	2.9	187
18	Ligelizumab for Chronic Spontaneous Urticaria. New England Journal of Medicine, 2019, 381, 1321-1332.	27.0	187

#	Article	IF	CITATIONS
19	Development and construct validation of the angioedema quality of life questionnaire. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1289-1298.	5.7	182
20	Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. Journal of Allergy and Clinical Immunology, 2017, 139, 1059-1061.e1.	2.9	167
21	The role and relevance of mast cells in urticaria. Immunological Reviews, 2018, 282, 232-247.	6.0	165
22	IL-9 Production by Regulatory T Cells Recruits Mast Cells That Are Essential for Regulatory T Cell-Induced Immune Suppression. Journal of Immunology, 2011, 186, 83-91.	0.8	160
23	TLR3-induced activation of mast cells modulates CD8+ T-cell recruitment. Blood, 2005, 106, 978-987.	1.4	157
24	A Beneficial Role for Immunoglobulin E in Host Defense against Honeybee Venom. Immunity, 2013, 39, 963-975.	14.3	151
25	European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1059-1065.	2.4	150
26	Successful treatment of solar urticaria with antiâ€immunoglobulin E therapy. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 1563-1565.	5.7	149
27	Development, validation, and initial results of the Angioedema Activity Score. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1185-1192.	5.7	147
28	Mast cells orchestrate type 2 immunity to helminths through regulation of tissue-derived cytokines. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6644-6649.	7.1	145
29	The definition and diagnostic testing of physical and cholinergic urticarias – EAACI/GA ² LEN/EDF/UNEV consensus panel recommendations. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1715-1721.	5.7	143
30	Mast cell chymase reduces the toxicity of Gila monster venom, scorpion venom, and vasoactive intestinal polypeptide in mice. Journal of Clinical Investigation, 2011, 121, 4180-4191.	8.2	134
31	Anti-Immunoglobulin E Treatment of Patients with Recalcitrant Physical Urticaria. International Archives of Allergy and Immunology, 2011, 154, 177-180.	2.1	133
32	Early macrophage influx to sites of cutaneous granuloma formation is dependent on MIP-1α/β released from neutrophils recruited by mast cell–derived TNFα. Blood, 2003, 101, 210-215.	1.4	130
33	Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: A systematic review. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1440-1460.	5.7	124
34	Skin mast cells control T cellâ€dependent host defense in Leishmania major infections. FASEB Journal, 2006, 20, 2460-2467.	0.5	123
35	Retreatment With Omalizumab Results in Rapid Remission in Chronic Spontaneous and Inducible Urticaria. JAMA Dermatology, 2014, 150, 288.	4.1	123
36	Autologous Whole Blood Injections to Patients with Chronic Urticaria and a Positive Autologous Serum Skin Test: A Placebo-Controlled Trial. Dermatology, 2006, 212, 150-159.	2.1	120

#	Article	IF	CITATIONS
37	Immunoglobulin E-Mediated Autoimmunity. Frontiers in Immunology, 2018, 9, 689.	4.8	116
38	Neurotensin increases mortality and mast cells reduce neurotensin levels in a mouse model of sepsis. Nature Medicine, 2008, 14, 392-398.	30.7	114
39	Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRl-positive cells in the skin. Theranostics, 2017, 7, 1266-1276.	10.0	113
40	Successful treatment of cholinergic urticaria with antiâ€immunoglobulin E therapy. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 247-249.	5.7	112
41	High Prevalence of Mental Disorders and Emotional Distress in Patients with Chronic Spontaneous Urticaria. Acta Dermato-Venereologica, 2011, 91, 557-561.	1.3	110
42	Definition, aims, and implementation of <scp>GA</scp> ² <scp>LEN</scp> Urticaria Centers of Reference and Excellence. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 1210-1218.	5.7	110
43	Interleukinâ€31 does not induce immediate itch in atopic dermatitis patients and healthy controls after skin challenge. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 113-117.	5.7	108
44	Effect of omalizumab on angioedema in H ₁ â€antihistamineâ€resistant chronic spontaneous urticaria patients: results from Xâ€ <scp>ACT</scp> , a randomized controlled trial. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 1135-1144.	5.7	108
45	Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020. International Archives of Allergy and Immunology, 2020, 181, 321-333.	2.1	108
46	Mast cell functions in the innate skin immune system. Immunobiology, 2008, 213, 251-260.	1.9	104
47	IL-15 constrains mast cell–dependent antibacterial defenses by suppressing chymase activities. Nature Medicine, 2007, 13, 927-934.	30.7	102
48	Effector and potential immunoregulatory roles of mast cells in IgE-associated acquired immune responses. Current Opinion in Immunology, 2006, 18, 751-760.	5.5	100
49	A new role for neurotrophins: involvement of brainâ€derived neurotrophic factor and neurotrophinâ€4 in hair cycle control. FASEB Journal, 1999, 13, 395-410.	0.5	93
50	Eosinopenia, in Chronic Spontaneous Urticaria, Is Associated with High Disease Activity, Autoimmunity, and Poor Response to Treatment. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 318-325.e5.	3.8	93
51	Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial. Journal of Allergy and Clinical Immunology, 2017, 140, 864-867.e5.	2.9	92
52	Skin Barrier Damage and Itch: Review of Mechanisms, Topical Management and Future Directions. Acta Dermato-Venereologica, 2019, 99, 1201-1209.	1.3	92
53	Murine mast cells secrete a unique profile of cytokines and prostaglandins in response to distinct TLR2 ligands. Experimental Dermatology, 2009, 18, 437-444.	2.9	91
54	Efficacy and safety of canakinumab in Schnitzler syndrome: AÂmulticenter randomized placebo-controlled study. Journal of Allergy and Clinical Immunology, 2017, 139, 1311-1320.	2.9	89

#	Article	IF	CITATIONS
55	Mast cells as protectors of health. Journal of Allergy and Clinical Immunology, 2019, 144, S4-S18.	2.9	88
56	Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial. Journal of the American Academy of Dermatology, 2019, 80, 1395-1402.	1.2	82
57	A New Role for Neurotrophin-3. American Journal of Pathology, 1998, 153, 785-799.	3.8	81
58	Control of Pseudomonas aeruginosa Skin Infections in Mice Is Mast Cell-Dependent. American Journal of Pathology, 2007, 170, 1910-1916.	3.8	80
59	The Urticaria Activity Score—Validity, Reliability, and Responsiveness. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1185-1190.e1.	3.8	78
60	Potential blood biomarkers in chronic spontaneous urticaria. Clinical and Experimental Allergy, 2017, 47, 19-36.	2.9	76
61	Mast cell–driven skin inflammation is impaired in the absence of sensory nerves. Journal of Allergy and Clinical Immunology, 2008, 121, 955-961.	2.9	75
62	Methods report on the development of the 2013 revision and update of the <scp>EAACI</scp> / <scp>GA²LEN</scp> /cscp>EDF/ <scp>WAO</scp> guideline for the definition, classification, diagnosis, and management of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, e1-29.	5.7	75
63	Mast cells rescue implantation defects caused by c-kit deficiency. Cell Death and Disease, 2013, 4, e462-e462.	6.3	74
64	Executive summary of the methods report for †The EAACI/GA ² LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update'. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1145-1146.	5.7	74
65	Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 2406-2408.	5.7	74
66	The role of interleukin-1 in allergy-related disorders. Current Opinion in Allergy and Clinical Immunology, 2012, 12, 477-484.	2.3	73
67	Omalizumab is effective in symptomatic dermographism—results of a randomized placebo-controlled trial. Journal of Allergy and Clinical Immunology, 2017, 140, 870-873.e5.	2.9	73
68	Autoimmune chronic spontaneous urticaria. Journal of Allergy and Clinical Immunology, 2022, 149, 1819-1831.	2.9	73
69	Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases. Nature Reviews Immunology, 2022, 22, 294-308.	22.7	72
70	A randomized, doubleâ€blind, comparative study of standardâ€dose rabeprazole and highâ€dose omeprazole in gastroâ€oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 2002, 16, 479-485.	3.7	71
71	New biological treatments for asthma and skin allergies. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 546-560.	5.7	70
72	Mas-related G protein–coupled receptor X2 and its activators in dermatologic allergies. Journal of Allergy and Clinical Immunology, 2021, 147, 456-469.	2.9	70

#	Article	IF	CITATIONS
73	Responsiveness and minimal important difference of the urticaria control test. Journal of Allergy and Clinical Immunology, 2017, 140, 1710-1713.e11.	2.9	68
74	Frequency and clinical implications of skin autoreactivity to serum versus plasma in patients with chronic urticaria. Journal of Allergy and Clinical Immunology, 2009, 123, 705-706.	2.9	67
75	Pathophysiology of itch and new treatments. Current Opinion in Allergy and Clinical Immunology, 2011, 11, 420-427.	2.3	66
76	Peltier effect–based temperature challenge: An improved method for diagnosing cold urticaria. Journal of Allergy and Clinical Immunology, 2004, 114, 1224-1225.	2.9	63
77	Chronic pruritus – pathogenesis, clinical aspects and treatment. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 1249-1260.	2.4	62
78	Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. Annals of Allergy, Asthma and Immunology, 2010, 104, 86-92.	1.0	62
79	Substance P Is Upregulated in the Serum of Patients with Chronic Spontaneous Urticaria. Journal of Investigative Dermatology, 2014, 134, 2833-2836.	0.7	61
80	A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria. Journal of Allergy and Clinical Immunology, 2016, 138, 1730-1732.	2.9	60
81	Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence. Clinical Reviews in Allergy and Immunology, 2020, 59, 38-45.	6.5	60
82	Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab. Journal of Allergy and Clinical Immunology, 2010, 126, 665-666.	2.9	59
83	The role of eosinophils in chronic spontaneous urticaria. Journal of Allergy and Clinical Immunology, 2020, 145, 1510-1516.	2.9	59
84	Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1793-1802.e2.	3.8	58
85	Innate immunity and allergy in the skin. Current Opinion in Immunology, 2009, 21, 687-693.	5.5	57
86	Looking forward to new targeted treatments for chronic spontaneous urticaria. Clinical and Translational Allergy, 2017, 7, 1.	3.2	57
87	S2k‣eitlinie zur Diagnostik und Therapie des chronischen Pruritus – Update – Kurzversion. JDDG - Journal of the German Society of Dermatology, 2017, 15, 860-873.	0.8	56
88	Mast cells are critical for controlling the bacterial burden and the healing of infected wounds. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 20500-20504.	7.1	55
89	Who is really in control of skin immunity underphysiologicalcircumstances - lymphocytes, dendritic cells or keratinocytes?. Experimental Dermatology, 2006, 15, 913-916.	2.9	54
90	Role and Relevance of Mast Cells in Fungal Infections. Frontiers in Immunology, 2012, 3, 146.	4.8	54

#	Article	IF	CITATIONS
91	Practical algorithm for diagnosing patients with recurrent wheals or angioedema. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 816-819.	5.7	53
92	German Version of ItchyQoL: Validation and Initial Clinical Findings. Acta Dermato-Venereologica, 2013, 93, 562-568.	1.3	53
93	Mast cells: makers and breakers of allergic inflammation. Current Opinion in Allergy and Clinical Immunology, 2009, 9, 427-430.	2.3	52
94	Efficacy and safety of canakinumab in urticarial vasculitis: An open-label study. Journal of Allergy and Clinical Immunology, 2013, 132, 751-754.e5.	2.9	52
95	Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e112-e113.	2.4	52
96	Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial. Nature Medicine, 2021, 27, 1961-1969.	30.7	52
97	The <i>status quo</i> and <i>quo vadis</i> of mast cells. Experimental Dermatology, 2005, 14, 923-929.	2.9	51
98	Inflammatory Murine Skin Responses to UV-B Light Are Partially Dependent on Endothelin-1 and Mast Cells. American Journal of Pathology, 2006, 169, 815-822.	3.8	51
99	Benefit of mepolizumab treatment in a patient with chronic spontaneous urticaria. JDDG - Journal of the German Society of Dermatology, 2018, 16, 477-478.	0.8	51
100	Omalizumab rapidly improves angioedemaâ€related quality of life in adult patients with chronic spontaneous urticaria: Xâ€ <scp>ACT</scp> study data. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 576-584.	5.7	51
101	Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases. Frontiers in Medicine, 0, 9, .	2.6	51
102	Mast cells protect from post-traumatic spinal cord damage in mice by degrading inflammation-associated cytokines via mouse mast cell protease 4. Neurobiology of Disease, 2014, 62, 260-272.	4.4	50
103	Mast Cells Limit the Exacerbation of Chronic Allergic Contact Dermatitis in Response to Repeated Allergen Exposure. Journal of Immunology, 2016, 197, 4240-4246.	0.8	50
104	Comparison and interpretability of the available urticaria activity scores. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 251-255.	5.7	50
105	Validation of the Angioedema Control Test (AECT)—A Patient-Reported Outcome Instrument for Assessing Angioedema Control. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2050-2057.e4.	3.8	50
106	<i>Fasciola hepatica</i> Tegumental Coat Impairs Mast Cells' Ability To Drive Th1 Immune Responses. Journal of Immunology, 2013, 190, 2873-2879.	0.8	49
107	Omalizumab in chronic urticaria. Current Opinion in Allergy and Clinical Immunology, 2012, 12, 406-411.	2.3	48
108	Mast cells protect from postâ€ŧraumatic brain inflammation by the mast cellâ€specific chymase <i>mouse mast cell proteaseâ€4</i> . FASEB Journal, 2013, 27, 920-929.	0.5	48

#	Article	IF	CITATIONS
109	Nonâ€pathogenic commensal <i>Escherichia coli</i> bacteria can inhibit degranulation of mast cells. Experimental Dermatology, 2008, 17, 427-435.	2.9	47
110	Development of the Angioedema Control Test—A patientâ€reported outcome measure that assesses disease control in patients with recurrent angioedema. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1165-1177.	5.7	47
111	IFSI-guideline on chronic prurigo including prurigo nodularis. Itch (Philadelphia, Pa), 2020, 5, e42-e42.	0.2	47
112	Antihistamineâ€resistant urticaria factitia successfully treated with antiâ€immunoglobulin E therapy. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1494-1495.	5.7	46
113	Rupatadine improves quality of life in mastocytosis: a randomized, doubleâ€blind, placeboâ€controlled trial. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 949-952.	5.7	46
114	Autoimmune Diseases Are Linked to Type IIb Autoimmune Chronic Spontaneous Urticaria. Allergy, Asthma and Immunology Research, 2021, 13, 545.	2.9	46
115	Chronic nodular prurigo: clinical profile and burden. A European crossâ€sectional study. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2373-2383.	2.4	44
116	Atopic dermatitis in children: management of pruritus. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 2-8.	2.4	43
117	Pruritus: an overview of current concepts. Veterinary Dermatology, 2011, 22, 121-131.	1.2	41
118	Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant. Acta Dermato-Venereologica, 2018, 98, 26-31.	1.3	40
119	Critical role of IL-10 in the induction of low zone tolerance to contact allergens. Journal of Clinical Investigation, 2003, 112, 432-439.	8.2	40
120	Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU). Acta Dermato-Venereologica, 2019, 99, 379-385.	1.3	40
121	Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. JDDG - Journal of the German Society of Dermatology, 2013, 11, 971-978.	0.8	39
122	Acquired cold urticaria symptoms can be safely prevented by ebastine. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 1465-1468.	5.7	38
123	A novel method to generate and culture human mast cells: Peripheral CD34+ stem cell-derived mast cells (PSCMCs). Journal of Immunological Methods, 2014, 413, 62-68.	1.4	37
124	Anaphylaxis caused by mosquito allergy in systemic mastocytosis. Lancet, The, 2013, 382, 1380.	13.7	35
125	Imaging glioma biology: spatial comparison of amino acid PET, amide proton transfer, and perfusion-weighted MRI in newly diagnosed gliomas. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1468-1475.	6.4	35
126	Distinct Roles for Nerve Growth Factor and Brain-Derived Neurotrophic Factor in Controlling the Rate of Hair Follicle Morphogenesis. Journal of Investigative Dermatology, 2000, 114, 314-320.	0.7	32

#	Article	lF	CITATIONS
127	Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: A randomized, doubleâ€blind, placeboâ€controlled study. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 141-151.	5.7	32
128	Pruritus and sleep disturbances in patients with psoriasis. Archives of Dermatological Research, 2020, 312, 103-111.	1.9	32
129	T cell killing by tolerogenic dendritic cells protects mice from allergy. Journal of Clinical Investigation, 2011, 121, 3860-3871.	8.2	31
130	Neurotrophin-3 regulates mast cell functions in neonatal mouse skin. Experimental Dermatology, 2004, 13, 273-281.	2.9	29
131	Histamine, TNF, C5a, IL-6, -9, -18, -31, -33, TSLP, Neopterin, and VECF are not elevated in chronic spontaneous urticaria. Journal of Dermatological Science, 2013, 70, 222-225.	1.9	29
132	Definition, aims, and implementation of GA ² LEN/HAEi Angioedema Centers of Reference and Excellence. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2115-2123.	5.7	29
133	A group of cationic amphiphilic drugs activates MRGPRX2 and induces scratching behavior in mice. Journal of Allergy and Clinical Immunology, 2021, 148, 506-522.e8.	2.9	29
134	Development and Validation of a Questionnaire for the Assessment of Pelvic Floor Disorders and Their Risk Factors During Pregnancy and Post Partum. Geburtshilfe Und Frauenheilkunde, 2017, 77, 358-365.	1.8	29
135	Polidocanol inhibits cowhage ―but not histamineâ€induced itch in humans. Experimental Dermatology, 2014, 23, 922-923.	2.9	28
136	The characteristics and impact of pruritus in adult dermatology patients: A prospective, cross-sectional study. Journal of the American Academy of Dermatology, 2021, 84, 691-700.	1.2	28
137	Mast cells protect from skin tumor development and limit tumor growth during cutaneous <i>de novo</i> carcinogenesis in a <scp>K</scp> itâ€dependent mouse model. Experimental Dermatology, 2014, 23, 159-164.	2.9	27
138	A Role for Bax in the Regulation of Apoptosis in Mouse Mast Cells. Journal of Investigative Dermatology, 2000, 114, 1205-1206.	0.7	26
139	Chronic pruritus associated with dermatologic disease in infancy and childhood: Update from an interdisciplinary group of dermatologists and pediatricians. Pediatric Allergy and Immunology, 2013, 24, 527-539.	2.6	26
140	Neues von der internationalen Leitlinie für Diagnostik und Therapie der chronischen Urtikaria. JDDG - Journal of the German Society of Dermatology, 2013, 11, 971-979.	0.8	26
141	Diagnosis and treatment of chronic inducible urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2550-2553.	5.7	26
142	Management of urticarial vasculitis: A worldwide physician perspective. World Allergy Organization Journal, 2020, 13, 100107.	3.5	26
143	Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A oneâ€year extension study. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2175-2184.	5.7	26
144	Mast cells, cortistatin, and its receptor, MRGPRX2, are linked to the pathogenesis of chronic prurigo. Journal of Allergy and Clinical Immunology, 2022, 149, 1998-2009.e5.	2.9	26

#	Article	IF	CITATIONS
145	Patients with chronic urticaria exhibit increased rates of sensitisation to <i>Candida albicans</i> , but not to common moulds. Mycoses, 2009, 52, 334-338.	4.0	25
146	Dupilumab in Treatment of Chronic Prurigo: A Case Series and Literature Review. Acta Dermato-Venereologica, 2019, 99, 905-906.	1.3	25
147	Real-life treatment of cholinergic urticaria with omalizumab. Journal of Allergy and Clinical Immunology, 2019, 143, 788-791.e8.	2.9	25
148	Position Statement: Linear prurigo is a subtype of chronic prurigo. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 263-266.	2.4	24
149	Rupatadine for the treatment of allergic rhinitis and urticaria. Expert Review of Clinical Immunology, 2011, 7, 15-20.	3.0	23
150	S2k Guidelines for the diagnosis and treatment of chronic pruritus – update – short version. JDDG - Journal of the German Society of Dermatology, 2017, 15, 860-872.	0.8	23
151	Who is really in control of skin immunity underphysiologicalcircumstances - lymphocytes, dendritic cells or keratinocytes?. Experimental Dermatology, 2006, 15, 913-929.	2.9	23
152	Mast cells determine the magnitude of bacterial toxinâ€induced skin inflammation. Experimental Dermatology, 2009, 18, 160-166.	2.9	22
153	Chronic Spontaneous Urticaria: How to Assess Quality of Life in Patients Receiving Treatment. Archives of Dermatology, 2011, 147, 1221.	1.4	22
154	Human Mast Cell Tryptase Is a Potential Treatment for Snakebite Envenoming Across Multiple Snake Species. Frontiers in Immunology, 2018, 9, 1532.	4.8	22
155	Updosing of bilastine is effective in moderate to severe chronic spontaneous urticaria: A realâ€life study. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 2073-2075.	5.7	22
156	Mast cells and IgE in defense against lethality of venoms: Possible "benefit―of allergy. Allergo Journal International, 2020, 29, 46-62.	2.0	22
157	Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4 act as "epitheliotrophins" in murine skin. Laboratory Investigation, 1999, 79, 557-72.	3.7	22
158	Prevention of signs and symptoms of dermographic urticaria by single-dose ebastine 20 mg. Clinical and Experimental Dermatology, 2009, 34, e137-e140.	1.3	21
159	The Diagnostic Workup in Chronic Spontaneous Urticaria—What to Test and Why. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2274-2283.	3.8	21
160	Chronic Nodular Prurigo: A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and Satisfaction. Acta Dermato-Venereologica, 2021, 101, adv00403.	1.3	20
161	Treatment of notalgia paraesthetica with an 8% capsaicin patch. British Journal of Dermatology, 2011, 165, 1359-1361.	1.5	18
162	Membraneâ€bound stem cell factor is the major but not only driver of fibroblastâ€induced murine skin mast cell differentiation. Experimental Dermatology, 2017, 26, 255-262.	2.9	18

#	Article	IF	CITATIONS
163	Effects of Antihistamines on Innate Immune Responses to Severe Bacterial Infection in Mice. International Archives of Allergy and Immunology, 2011, 155, 355-360.	2.1	17
164	Effective Control of Recalcitrant Pruritus by Bevacizumab: A Possible Role for Vascular Endothelial Growth Factor in Chronic Itch?. Acta Dermato-Venereologica, 2013, 93, 175-179.	1.3	17
165	Skin provocation tests may help to diagnose atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 1745-1752.	5.7	17
166	In chronic spontaneous urticaria, high numbers of dermal endothelial cells, but not mast cells, are linked to recurrent angio-oedema. Clinical and Experimental Dermatology, 2018, 43, 131-136.	1.3	17
167	Protocols for the Induction and Evaluation of Systemic Anaphylaxis in Mice. Methods in Molecular Biology, 2013, 1032, 133-138.	0.9	17
168	Mast cells cultured from IL-3-treated mice show impaired responses to bacterial antigen stimulation. Inflammation Research, 2012, 61, 79-85.	4.0	16
169	The effects of Fasciola hepatica tegumental antigens on mast cell function. International Journal for Parasitology, 2013, 43, 531-539.	3.1	16
170	Omalizumab may not inhibit mast cell and basophil activation <i>in vitro</i> . Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1832-1836.	2.4	16
171	Lower IgA Levels in Chronic Spontaneous Urticaria Are Associated With Lower IgE Levels and Autoimmunity. Frontiers in Immunology, 2021, 12, 657211.	4.8	15
172	Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: Results of a phase 1a/b randomised doubleâ€blind placeboâ€controlled study. British Journal of Clinical Pharmacology, 2021, 87, 4797-4808.	2.4	15
173	Prevalence and factors associated with sleep disturbance in adult patients with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 688-697.	2.4	15
174	Best practices, new perspectives and the perfect emollient: optimizing the management of contact dermatitis. Journal of Dermatological Treatment, 2018, 29, 241-251.	2.2	14
175	Retardation of Hair Follicle Development by the Deletion of TrkC, High-Affinity Neurotrophin-3 Receptor. Journal of Investigative Dermatology, 1999, 113, 425-427.	0.7	13
176	Palliative treatment of skin metastases in dermatoâ€oncology. JDDG - Journal of the German Society of Dermatology, 2013, 11, 1041-1046.	0.8	13
177	Expert consensus on practical aspects in the treatment of chronic urticaria. Allergo Journal International, 2021, 30, 64-75.	2.0	13
178	Magistralrezeptur und Pruritustherapie - Was ist etabliert, was hat sich bewÄ ¤ rt, was ist neu?. JDDG - Journal of the German Society of Dermatology, 2013, 11, 1049-1056.	0.8	12
179	Mast cells: Promoters of health and modulators of disease. Journal of Allergy and Clinical Immunology, 2019, 144, S1-S3.	2.9	12
180	Characterization of the effects on pruritus by novel treatments for atopic dermatitis. JDDG - Journal of the German Society of Dermatology, 2022, 20, 150-156.	0.8	12

#	Article	IF	CITATIONS
181	Evidence that the endothelin AÂreceptor can enhance IgE-dependent anaphylaxis in mice. Journal of Allergy and Clinical Immunology, 2011, 128, 424-426.e1.	2.9	11
182	The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Przeglad Dermatologiczny, 2015, 2, 155-179.	0.1	11
183	Increased angiogenesis and <scp>VEGF</scp> expression correlates with disease severity in prurigo patients. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1357-1361.	2.4	11
184	Poster Discussion Session PDS. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 118-272.	5.7	11
185	Itch Management: Topical Agents. Current Problems in Dermatology, 2016, 50, 40-45.	0.7	11
186	Mast cells are critical for the limitation of thrombinâ€induced skin inflammation. Experimental Dermatology, 2018, 27, 50-57.	2.9	11
187	Miltefosine: a novel treatment option for mast cell-mediated diseases. Journal of Dermatological Treatment, 2013, 24, 244-249.	2.2	10
188	Galactose-α-1,3-Galactose Allergy Is Not a Hitherto Unrecognized Cause of Chronic Spontaneous Urticaria. International Archives of Allergy and Immunology, 2015, 167, 250-252.	2.1	10
189	Use of biologics in chronic spontaneous urticaria – beyond omalizumab therapy?. Allergologie Select, 2021, 5, 89-95.	3.1	10
190	Rupatadine in Established Treatment Schemes Improves Chronic Spontaneous Urticaria Symptoms and Patients' Quality of Life: a Prospective, Non-interventional Trial. Dermatology and Therapy, 2015, 5, 217-230.	3.0	9
191	Chymase-Cre; Mcl-1fl/fl Mice Exhibit Reduced Numbers of Mucosal Mast Cells. Frontiers in Immunology, 2019, 10, 2399.	4.8	9
192	The response to treatment in chronic spontaneous urticaria depends on how it is measured. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2055-2056.e4.	3.8	9
193	Sleep disturbance in adult dermatologic patients: A cross-sectional study on prevalence, burden, and associated factors. Journal of the American Academy of Dermatology, 2021, 85, 910-922.	1.2	9
194	The Classification, Pathogenesis, Diagnostic Workup, and Management of Urticaria: An Update. Handbook of Experimental Pharmacology, 2021, 268, 117-133.	1.8	9
195	Treatments for chronic pruritus outside of the box. Experimental Dermatology, 2019, 28, 1476-1481.	2.9	8
196	Severe contact dermatitis caused by urushiol in Japanese lacquer. Contact Dermatitis, 2019, 80, 55-56.	1.4	8
197	In Chronic Spontaneous Urticaria, Comorbid Depression Linked to Higher Disease Activity, and Substance P Levels. Frontiers in Psychiatry, 2021, 12, 667978.	2.6	8
198	Automatic screening of selfâ€evaluation apps for urticaria and angioedema shows a high unmet need. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3810-3813.	5.7	8

#	Article	IF	CITATIONS
199	A comprehensive, triâ€national, crossâ€sectional analysis of characteristics and impact of pruritus in psoriasis. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 2064-2075.	2.4	8
200	Erfolgreiche Behandlung des hereditäen Angioödems mit dem Bradykinin-B2-Rezeptor-Antagonisten Icatibant. JDDG - Journal of the German Society of Dermatology, 2010, 8, 272-274.	0.8	7
201	Comparison of pruritus and sensory qualities induced by capsaicin, histamine and cowhage. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1755-1761.	2.4	7
202	Evidence for Non-Allergic Mast Cell Activation in Pollen-Associated Inflammation. Journal of Investigative Dermatology, 2011, 131, 987-990.	0.7	6
203	Magistral formulations and pruritus therapy – What is established, what is confirmed, what is new?. JDDG - Journal of the German Society of Dermatology, 2013, 11, 1049-1055.	0.8	6
204	Reply. Journal of Allergy and Clinical Immunology, 2018, 141, 1166-1167.	2.9	6
205	Effective treatment with mepolizumab in a patient with refractory Wells syndrome. JDDG - Journal of the German Society of Dermatology, 2020, 18, 737-739.	0.8	6
206	A distinctive bullous skin reaction associated with enfortumab vedotinâ€ejfv treatment for metastatic urothelial cancer: A case report. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1781-1783.	0.8	6
207	Successful treatment of hereditary angioedema with bradykinin B2â€receptor antagonist icatibant. JDDG - Journal of the German Society of Dermatology, 2010, 8, 272-274.	0.8	5
208	Anti-pruritic Effect of Sertaconazole 2% Cream in Atopic Dermatitis Subjects: A Prospective, Randomized, Double-blind, Vehicle-controlled, Multi-centre Clinical Trial of Efficacy, Safety and Local Tolerability. Acta Dermato-Venereologica, 2014, 96, 792-6.	1.3	5
209	H1-antihistamine inhibition of histamine- and codeine-induced wheals does not predict response in chronic cold urticaria. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2043-2044.	3.8	5
210	Characterization of cowhageâ€induced pruritus in inflamed and nonâ€inflamed skin. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 202-206.	2.4	5
211	Effectiveness of canakinumab treatment in Schnitzler's syndrome: a multi-center randomized placebo-controlled study. Pediatric Rheumatology, 2015, 13, .	2.1	4
212	Effective treatment of a lymphocytic variant of hypereosinophilic syndrome with reslizumab. JDDG - Journal of the German Society of Dermatology, 2019, 17, 1171-1172.	0.8	4
213	Prevalence and relevance of skin autoreactivity in chronic urticaria. Expert Review of Dermatology, 2009, 4, 655-663.	0.3	3
214	Flare Size but Not Intensity Reflects Histamine-Induced Itch. Skin Pharmacology and Physiology, 2020, 33, 244-252.	2.5	3
215	Baricitinib rapidly and sustainably relieves a patient from chronic pruritus of unknown origin refractory to dupilumab. JAAD Case Reports, 2021, 15, 36-38.	0.8	3
216	Mast Cell-Mediated Reactions In Vivo. Methods in Molecular Biology, 2014, 1192, 239-247.	0.9	3

#	Article	IF	CITATIONS
217	Mast cells, basophils, and mastocytosis. , 2013, , 284-297.		3
218	Differential effects of skin nerves on allergic skin inflammation. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 496-497.	5.7	2
219	A Case of Muckle-Wells Syndrome due to novel NLRP3 mutation. JDDG - Journal of the German Society of Dermatology, 2018, 16, 1250-1252.	0.8	2
220	Are we facing a change in the treatment of chronic pruritus?. British Journal of Dermatology, 2019, 181, 877-878.	1.5	2
221	Wytyczne EAACI/GA2LEN/EDF/WAO dotyczÄce definicji, klasyfikacji, diagnostyki i leczenia pokrzywki. Alergologia Polska - Polish Journal of Allergology, 2020, 7, 1-28.	0.0	2
222	A Systematic Review of Aquagenic Urticaria - Subgroups and Treatment Options. Journal of Allergy and Clinical Immunology: in Practice, 2022, , .	3.8	2
223	STAT3 gain-of-function is not responsible for low total IgE levels in patients with autoimmune chronic spontaneous urticaria. Frontiers in Immunology, 0, 13, .	4.8	2
224	Development of a standardized experimental itch model in humans. Journal of the American Academy of Dermatology, 2014, 70, AB42.	1.2	1
225	Nutzen von Mepolizumab bei einer Patientin mit chronischer spontaner Urtikaria. JDDG - Journal of the German Society of Dermatology, 2018, 16, 476-477.	0.8	1
226	Pathomechanismus von Angioödemen. Allergologie, 2013, 36, 85-91.	0.1	1
227	New roles for neurotrophin-3, neurotrophin-4 and brain-derived neurotrophic factor: Involvement in hair growth control. Journal of Dermatological Science, 1998, 16, S9.	1.9	Ο
228	Modulation of skin mast cell functions in situ by neurotrophin-3. Journal of Dermatological Science, 1998, 16, S165.	1.9	0
229	Viewpoint 1. Experimental Dermatology, 2003, 12, 887-891.	2.9	0
230	Viewpoint 5. Experimental Dermatology, 2006, 15, 924-925.	2.9	0
231	Mast cells, basophils and mastocytosis. , 2008, , 345-360.		Ο
232	Type 2 Immunity Can Have a Protective Role In Host Defense Against Venoms In Mice. Journal of Allergy and Clinical Immunology, 2014, 133, AB90.	2.9	0
233	IgE Antibodies and FcεRI Are Critical For Acquired Resistance Against Honeybee Venom In Mice. Journal of Allergy and Clinical Immunology, 2014, 133, AB225.	2.9	Ο
234	Wytyczne EAACI/GA2LEN/EDF/WAO dotyczÄce definicji, klasyfikacji, rozpoznawania i leczenia pokrzywki: weryfikacja z 2013 roku z poprawkami. Alergologia Polska - Polish Journal of Allergology, 2015, 2, T1-T23.	0.0	0

#	Article	IF	CITATIONS
235	Omalizumab normalizes gene expression in lesional skin of patients with chronic spontaneous urticaria: Results from a randomized, double-blind, placebo-controlled study. Journal of the American Academy of Dermatology, 2016, 74, AB64.	1.2	0
236	041 Prevalence, characteristics and burden of pruritus in chronic dermatoses. Journal of Investigative Dermatology, 2017, 137, S199.	0.7	0
237	057 The role of substance P and its receptor NK1R in chronic prurigo: Results from a randomized, controlled trial with topical aprepitant. Journal of Investigative Dermatology, 2017, 137, S202.	0.7	0
238	Omalizumab improves angioedema-related quality of life impairment in chronic spontaneous urticaria patients: Results from the X-ACT study. Journal of the American Academy of Dermatology, 2018, 79, AB209.	1.2	0
239	Ein Fall von Muckle-Wells-Syndrom mit einer neuen NLRP3-Mutation. JDDG - Journal of the German Society of Dermatology, 2018, 16, 1250-1252.	0.8	0
240	Ligelizumab for Chronic Spontaneous Urticaria. New England Journal of Medicine, 2020, 382, 579-580.	27.0	0
241	Inducible Urticarias. , 2021, , 109-132.		0
242	Standard Operating Procedures: A Practical Approach. , 2010, , 141-151.		0
243	Neue Therapeutika beim Hereditäen Angioödem Â− unbeantwortete Fragen beim Hereditäen Angioödem. Allergologie, 2013, 36, 120-127.	0.1	0
244	Oral Allergy Syndrome. , 2014, , 37-50.		0
245	Mastzellen und Basophile. , 2016, , 69-75.		0
246	Anpassung der Therapiekonzepte: Chronische spontane Urtikaria – eine Autoimmunkrankheit. , 0, , .		0